Traders Sell Eli Lilly and Co. (LLY) on Strength (LLY)
Investors sold shares of Eli Lilly and Co. (NYSE:LLY) on strength during trading hours on Monday. $44.91 million flowed into the stock on the tick-up and $62.81 million flowed out of the stock on the tick-down, for a money net flow of $17.90 million out of the stock. Of all stocks tracked, Eli Lilly and had the 0th highest net out-flow for the day. Eli Lilly and traded up $0.39 for the day and closed at $81.98
Several research analysts have issued reports on LLY shares. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a research report on Tuesday, March 29th. Vetr downgraded shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating and set a $85.08 target price on the stock. in a report on Monday, April 18th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $91.00 target price on shares of Eli Lilly and in a report on Wednesday, July 6th. Societe Generale assumed coverage on shares of Eli Lilly and in a report on Wednesday, April 6th. They issued a “hold” rating and a $78.00 target price on the stock. Finally, Jefferies Group lifted their target price on shares of Eli Lilly and from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, July 14th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Eli Lilly and currently has a consensus rating of “Buy” and a consensus price target of $95.10.
The company has a market capitalization of $86.89 billion and a PE ratio of 37.78. The stock’s 50 day moving average price is $77.08 and its 200-day moving average price is $75.79.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 26th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.85 by $0.02. The company earned $4.87 billion during the quarter, compared to analyst estimates of $4.82 billion. During the same period last year, the company earned $0.87 earnings per share. The firm’s revenue was up 4.7% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Co. will post $3.56 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be issued a $0.51 dividend. The ex-dividend date of this dividend is Thursday, August 11th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.49%.
In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $79.54, for a total value of $16,703,400.00. Following the completion of the sale, the insider now directly owns 126,220,804 shares in the company, valued at $10,039,602,750.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Melissa S. Barnes sold 992 shares of Eli Lilly and stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $73.77, for a total value of $73,179.84. Following the completion of the sale, the senior vice president now owns 10,710 shares of the company’s stock, valued at $790,076.70. The disclosure for this sale can be found here.
Other hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Eli Lilly and by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 59,913,179 shares of the company’s stock worth $5,048,284,000 after buying an additional 1,552,428 shares during the last quarter. WBI Investments Inc. raised its stake in shares of Eli Lilly and by 14,739.0% in the fourth quarter. WBI Investments Inc. now owns 765,988 shares of the company’s stock worth $64,542,000 after buying an additional 760,826 shares during the last quarter. BHF Kleinwort Benson Group S.A. purchased a new stake in shares of Eli Lilly and during the fourth quarter worth approximately $39,409,000. Morgan Stanley raised its stake in shares of Eli Lilly and by 15.1% in the fourth quarter. Morgan Stanley now owns 3,510,398 shares of the company’s stock worth $295,785,000 after buying an additional 459,759 shares during the last quarter. Finally, IronBridge Capital Management LP purchased a new stake in shares of Eli Lilly and during the fourth quarter worth approximately $29,723,000.
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.